Class IIb & Class III Medical Devices
Non Pyrogenic – Sterile
ISO 13485 Certified
+2 Million Patients treated
Dedicated Kits for specific preparations
+ 200 published studies
To improve quality of life for patients, providing meaningful interventions
by way of Autologous Cell-Based Preparations & Tissue Engineering.
Live With Confidence
Maximize Your Potential
Retain Your Vigor
for Autologous Cellular Therapies
The Regen Lab technology is based on the use of a thixotropic gel to separate the blood components. This process is protected by many patents (US8529957, EP2073862, US2014010857). Thixotropy is a physical property of some gels. The gel acts as a mechanical separator of the blood components.
Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance. Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.
Categorized as Latest Global News and Events
Regen Lab Announces the Obtention of the New CE Certification Under Medical Device Regulation (EU MDR 2017/745) Validating the Safety and Performance of Its Proprietary Best-in-class PRP Solutions, Alone or Combined With Hyaluronic Acid May 15, 2023 08:00 AM Eastern Daylight Time LE MONT-SUR LAUSANNE, Switzerland–(BUSINESS WIRE)–Regen Lab, a global commercial-stage medical technology company specializing… Continue reading Home
Categorized as Blog
PRP – Rational/Indication Does current clinical evidence support the use of PRP for knee OA For which degrees of knee OA is PRP best indicated? Can PRP be used in severe knee OA (KL4)? Is PRP indicated for the treatment of Patellofemoral OA (PFOA)? Are there specific contraindications for the use of PRP for knee… Continue reading Home
Categorized as Blog
In April 2022, following the annual ESSKA congress, a group of experts published an important document stating their recommendations on the use of PRP in the management of knee osteoarthritis. This is a consensus paper which was obtained after more than 2 years of deliberations on the subject, answering 28 specific questions for which an… Continue reading Home
Since 2003, RegenLab® has been committed to the development of a unique expertise in the design and manufacture of high-quality medical devices, intended for the preparation of autologous cellular therapies prepared from the patient’s own blood, especially platelet-rich plasma. In 2009, a Good Manufacturing Practice (GMP) facility was completed in Mont-sur-Lausanne, Switzerland allowing RegenLab® to increase access to autologous cellular therapies around the world. The majority of our medical devices are now Developed and Manufactured in the USA, in Brooklyn, as of November 2021. As we look to the future, we remain committed to the development of standardized practices for emerging categories within Regenerative Medicine, for the benefit of public health and patient welfare.
Our Quality Management System operates within the framework of ISO 13485, under the Medical Device Single Audit Program (MDSAP).
Now is the time to step into the future of medicine.
Get connected with us to Learn More.
Our regional offices are